Avstera Therapeutics

Avstera Therapeutics is a biotechnology company focused on oncology, leveraging cutting-edge approaches to address critical immune challenges within the tumor microenvironment and committed to meeting the unmet needs of cancer patients. The company’s technology aims to harness the power of HDAC6 inhibitors to prevent the pro-tumor phenotypic conversion of macrophages and enhance macrophage-based anti-cancer immunotherapy. Avstera Therapeutics boasts a broad pipeline, including novel small molecules and biologics, focusing on fundamental science while employing advanced methods to break barriers in approach.